EGFR and non-small cell lung carcinoma: Osimertinib (AZD9291), a third-generation EGFR-TKI with activity against sensitive and resistant EGFR mutations, is the standard treatment in T790M-positive NSCLC patients after disease-progression on EGFR-TKIs [10], and it has received the approval by FDA and EMA.